Biofocus DPI, the service division of Galapagos, and Dart Neuroscience LLC (DNS) have announced collaboration agreements in drug discovery and compound management.
Total potential value of the contracts for Biofocus DPI is EUR4.1m over three years.
Biofocus DPI will develop a cell-based assay for DNS's drug discovery programmes for brain disorders, and perform high-throughput screening and hit expansion using its compound collections.
It will carry out compound management for DNS over the next three years.
